NYSE$OSCR
Oscar Health Inc · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
Oscar Health reported Q1 2026 total revenue of $4.65B and net income attributable to Oscar of $679.0M, with diluted EPS of $2.07.
Total revenue rose 53% to $4.65 billion on higher premium volume. Earnings from operations were $704.1 million; net income attributable to Oscar was $679.0 million, or $2.07 per diluted share ($0.92 prior year). Medical benefit ratio improved as membership and pricing actions took hold.
- Total revenue $4.65B (+53% YoY).
- Earnings from operations $704.1M.
- Net income $679.0M; diluted EPS $2.07.
- Premium revenue $4.58B.
Headline financials
Revenue & EPS history
Oscar Health · Revenue · Quarterly
$4.65B
Forward guidance
MD&A discusses membership growth and MLR targets; full-year guidance referenced qualitatively in risk factors.
Tailwinds
- Profitable quarter at scale with membership growth.
- Operating leverage on higher premiums.
- MLR improvement vs. prior periods.
Headwinds
- Regulatory risk in ACA markets.
- Medical cost trend uncertainty.
- Competitive pricing in exchanges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+3.7%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+7.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+30.0%
Q1 2025
Best reaction
-23.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +22.6% | +36.6% | |
| Q4 2025 | +1.7% | +6.0% | +2.7% | |
| Q3 2025 | -2.8% | -12.8% | -1.5% | |
| Q1 2025 | +30.0% | +28.7% | +18.0% | |
| Q4 2024 | +3.1% | -3.7% | +4.5% | |
| Q3 2024 | -12.9% | -12.8% | +0.4% | |
| Q2 2024 | +7.2% | +4.4% | -1.4% | |
| Q1 2024 | +9.3% | +14.1% | +2.8% | |
| Q4 2023 | +22.7% | +27.5% | +7.7% | |
| Q3 2023 | +23.5% | +24.5% | +42.0% | |
| Q2 2023 | +8.6% | +1.9% | -10.5% | |
| Q1 2023 | -8.8% | -6.6% | +17.8% | |
| Q4 2022 | +21.0% | +36.2% | -3.9% | |
| Q3 2022 | -23.9% | -4.5% | -11.3% | |
| Q2 2022 | +19.9% | +21.1% | -3.7% | |
| Q1 2022 | -8.9% | -2.0% | -25.0% | |
| Q4 2019 | +6.3% | +2.5% | +39.1% | |
| Q4 2021 | +2.4% | +15.6% | +21.9% | |
| Q3 2020 | -2.4% | -6.3% | -12.7% | |
| Q3 2021 | -23.3% | -25.2% | -33.0% | |
| Q2 2020 | -16.4% | -11.8% | +19.4% | |
| Q2 2021 | -0.9% | -12.0% | +17.9% | |
| Q4 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2021 | +3.6% | +4.2% | +14.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro